Search

Author/Creator Rasmussen, E

1. 427PPhase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma. (23rd October 2018)

Authors:
Moek, K L; Fiedler, W M; von Einem, J C; Verheul, H M; Seufferlein, T; de Groot, D J; Heinemann, V; Kebenko, M; Menke-van der Houven van Oordt, C W; Ettrich, T J; Rasmussen, E; Bogner, P; Sable, B; Stienen, S; de Vries, E G E
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A Pharmacokinetic and Safety Study of Trebananib, an Fc‐Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction. Issue 2 (9th June 2017)

Authors:
Wu, B; Lewis, LD; Harvey, RD; Rasmussen, E; Gamelin, E; Sun, Y‐N; Friberg, G; Koyner, JL; Dowlati, A; Maitland, ML
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 102:Issue 2(2017)
Page Start:
313
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗